SCHEMBL16657608

SCHEMBL16657608

CC(C)(C)OC(=O)N1CCC(C(C#N)c2ccc(Cl)cc2F)CC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.54
CYP3A5 P20815 2/20 0.54
FPR2 P25090 1/20 0.51
PROKR1 Q8TCW9 1/20 0.51
DPP4 P27487 2/20 0.48
GPR119 Q8TDV5 7/20 0.47
USP30 Q70CQ3 1/20 0.46
STS P08842 3/20 0.44
MMP13 P45452 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
DPP7 Q9UHL4 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30026879 1.00 CYP3A4 (0.54) CYP3A4CYP3A5FPR2PROKR1DPP4
SCHEMBL15536955 0.84 FPR2 (0.54) CYP3A4CYP3A5FPR2PROKR1DPP4
SCHEMBL16657606 0.83 CNR1 (0.52) FPR2PROKR1GPR119STSMEN1
SCHEMBL553509 0.80 GPR119 (0.49) GPR119USP30STSMEN1KMT2A
SCHEMBL553508 0.80 GPR119 (0.49) GPR119USP30STSMEN1KMT2A
SCHEMBL554690 0.80 GPR119 (0.49) GPR119USP30STSMEN1KMT2A
SCHEMBL23211814 0.78 MMP13 (0.52) DPP4GPR119MMP13MEN1KMT2A
SCHEMBL21381612 0.78 MMP13 (0.52) DPP4GPR119MMP13MEN1KMT2A
SCHEMBL29745437 0.78 NSD2 (0.44) DPP4GPR119STSMMP13NPC1
SCHEMBL23216540 0.78 NSD2 (0.44) DPP4GPR119STSMMP13NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200190059-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES TAKEDA PHARMACEUTICALS CO (JP) 2020-06-18 US disclosed
US-10544126-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-01-28 US disclosed
US-20190084962-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES TAKEDA PHARMACEUTICALS CO (JP) 2019-03-21 US disclosed
US-10167273-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-01-01 US disclosed
EP-2855449-B1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES TAKEDA PHARMACEUTICALS CO (JP) 2018-03-07 EP disclosed
US-20160376256-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-29 US disclosed
US-9475795-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-10-25 US disclosed
US-9475795-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-10-25 US disclosed
US-20150111922-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-23 US disclosed
US-20150111922-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190084962-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES PROKR1, GIPR, PROKR2 CYP3A4 3405/4885CYP3A5 2335/4885FPR2 3719/4885
US-20200190059-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES PROKR1, GIPR, PROKR2 CYP3A4 3405/4885CYP3A5 2335/4885FPR2 3719/4885
US-10544126-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases PROKR1, GIPR, PROKR2 CYP3A4 3405/4885CYP3A5 2335/4885FPR2 3719/4885
US-20160376256-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES PROKR1, GIPR, PROKR2 CYP3A4 3405/4885CYP3A5 2335/4885FPR2 3719/4885
US-10167273-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases PROKR1, GIPR, PROKR2 CYP3A4 3405/4885CYP3A5 2335/4885FPR2 3719/4885
US-20150111922-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES PROKR1, GIPR, PGC CYP3A4 4009/4885CYP3A5 1811/4885FPR2 3123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.